Thiothixene liquid

Such a good driver!" At lunch next day he probed Pumphrey with "Out last night with my brother and some friends of his. Gosh, what driving! Slippery `s glass. Thought I saw you hiking up the Bellevue Avenue Hill." "No, I wasn't--I didn't see you, " said Pumphrey, hastily, rather guiltily. Perhaps two days afterward Babbitt took Tanis to lunch at the Hotel Thornleigh. She who had seemed well content to wait for him at her flat had begun to hint with melancholy smiles that he must think but little of her if he never introduced her to his friends, if he was unwilling to be seen with her except at the movies. He thought of taking her to the "ladies' annex" of the Athletic Club, but that was too dangerous. He would have to introduce her and, oh, people might misunderstand and--He compromised on the Thornleigh. She was unusually smart, all in black: small black tricorne hat, short black caracul coat, loose and swinging, and austere high-necked black velvet frock at a time when most street costumes were like evening gowns. Perhaps she was too smart. Every one in the gold and oak restaurant of the Thornleigh was staring at her as Babbitt followed her to a table. He uneasily hoped that the head-waiter would give them a discreet place behind a pillar, but they were stationed on the center aisle. Tanis seemed not to notice her admirers; she smiled at Babbitt with a lavish "Oh, isn't this nice! What a peppy.

MISC. ELECTROLYTES NUTRITIONALS ELECTROLYTES NUTRITIONALS FISH OIL CAPS INTRALIPID EMUL MCT OIL OIL ORALYTE SOLN P.T.E. -5 SOLN PEDIALYTE SOLN BOOST CASEC POWD CHOICE DM LIQD DELIVER 2.0 LIQD ENFAMIL ENSURE GLUCERNA ISOCAL LIQD KINDERCAL TF LIQD KINDERCAL TF FIBER LIQD L-CARNITINE CAPS LIPISORB LIQD Use PA Form # 20420 & SGA Form This list of nutritionals is Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered incomplete. All nutritionals on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the still require a PA except for preferred drug s ; exists. As listed in MaineCare Policy, certain drugs require specific diagnoses for approval. the miscellaneous products listed as preferred. SGA form required for nutritionals unless member has a G I tube.
Attachment Site of CS Chain s ; on NGC Core Protein--As described above, when a wild type NGC cDNA was transfected into Neuro 2a cells, the expressed NGC bore CS chain s ; Figs. 5C and 7B ; . Its molecular size was almost the same as that of NGC in primary cultures of neocortical neurons Fig. 7A ; , 150 and 120 kDa before and after CHase ABC treatment, respectively. Therefore, by using this cell line, we determined the CS attachment site on the NGC core protein by site-directed mutagenesis. When a mutant NGC cDNA, which produces NGC with a mutation of S123A, was transfected into Neuro 2a cells, the NGC was observed as a band of 120 kDa regardless of CHase ABC digestion Fig. 7C ; . Another five mutant NGCs, including one with the mutation S38A Fig. 7D ; , were expressed as a chondroitinase-sensitive broad band of 150 kDa or a proteoglycan form. These results indicate that only one site, Ser-123, among the six potential sites on NGC was occupied by a CS chain. Although the NGC ectodomain can be phosphorylated by a casein kinase II-like kinase, the site of the phosphorylation is different from Ser-123 27, 28 ; . Cell Surface Localization of Normal NGC with a CS Chain and Mutant NGC without CS Chains in Neuro 2a Cells-- Because there is a possibility that CS glycosylation is necessary for transportation of NGC to the cell surface, we examined whether NGC with a mutation of S123A was transported to and existed at the cell surfaces of Neuro 2a cells by biotinylating surface proteins. When the cells expressing normal NGC, which bears a CS chain Fig. 5C ; , were subjected to biotinylation, many proteins were biotinylated Fig. 8A, lane 1 ; , including the 120-kDa doublet Fig. 8A, lane 2 ; that was immunoreactive with the anti-NGC antibody Fig. 8A, lane 3 ; . NGC with a mutation of S123A does not bear any CS chains as shown in Fig. 7C. Unexpectedly, the mutant NGC molecules were also biotinylated, when the cell surfaces of Neuro 2a cells stably expressing the mutant molecules were biotinylated Fig. 8B, lanes 2 and 3 ; . These findings indicate that NGC can be transported to the cell surface regardless of its CS glycosylation.

Agreement with previous reports, describing the transition from a metastable state to a stable equilibrium state, suggesting that tween 20 plays a role in stabilizing nuclei of bh 27 ; our surprise, the rate of tween 20-induced bh formation is faster than and tiagabine. Semen Analysis In CML 5. Thachil, J.V; Jewett, M.A.; Rider, W.D. 1981 ; : The effects of cancer and cancer therapy on male fertility. Journal of Urology 126 : pp 141-145. The Italian Co-opertive Study Group on Chronic Myeloid Leukemia 1994 ; : Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New England Journal of Medicine 333 : p 820. Van Thiel, D.H; Sherins, R.J; Myers, G.H; Devita, V.T.Jr, 1972 ; : Evidence for a specific seminiferous tubular factor affecting follicle-stimulating hormone secretion in man. Journal of Clinical investigation. 51 : 1009-1019. Wetzler, M; Kantarjian, H; Kurzrock, R. Talpaz, M. 1995 ; : Interferon-alpha therapy for chronic myelgenous leukemia. American Journal of Medicine. 99 : pp 402-411. WHO Laboratory Manual for the Examination of Human Semen and Semen Cervical mucus interaction. WHO Cambridge University Press, Cambridge, 1992. Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Dr. Hubertus Erlen, certify that: 1. I have reviewed this annual report on Form 20-F of Schering Aktiengesellschaft; 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report; 3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report; 4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures as defined in Exchange Act Rules 13a-14 and 15d-14 ; for the registrant and have: a ; designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared; b ; evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this annual report the "Evaluation Date" and c ; presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date; 5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors or persons performing the equivalent function ; : a ; all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and b ; any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and 6. The registrant's other certifying officers and I have indicated in this annual report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses. Date: March 18, 2003 By: s HUBERTUS ERLEN Chairman of the Board of Executive Directors and timolol.

Thiothixene alternative

References: 1. BrassIer B, Fnedel RO: A companson between chlorpromazine and thiothixene in a Veterans Administration hospital population. Psychosomatics 1971 12: 275-277. DiMascio A, Demirgian E: Study of the activating properties of thiothixene. Psychosomatics 1972: 13: 105-108. DiMaselo A, Demirgian E: Jobtrainin inthe rehabilitation ofthe chrome schizophrenic. Presented as a Scientific Exhibit atThe American Psychiatric Associat'on. Washington, DC, May 3-6, 1971. 4. Goldstein B, Weiner D, Banas F: Clinical evaluation of thiothixene in chronic ambulatory schizophrenic patients, in Lehmann HE, Ban TA ads ; : The Thioxanthenes: Modem Probiems of Pdamxaccpsychiatry Basel, Switzerland, S. Karger, 1969, vol 2, pp 45-52. 5. Dillenkoffer RL, Gallant ON, George RB, et a ; : Electrocardiographic evaluation of schizophrenic patients: A double-blind comparison. Presented as a Scientific Exhibit at The 125th Annual Meeting of the American Psychiatric Association, Dallas, May 1-4, 1972. 6. Data available on request from Roeng. BRIEF SUMMARY OF PRESCRIBING INFORMATION Navanea thlothlxene ; Capsules: 1 mg, 2 mg, 5 mg, 10 mg, 20 mg thiothlxene hydrachkirlde ; Concentrate: 5 mg mI, Intramuscular 2 mg mI, S mg mi Indicatiens: Navane is effective in the management of manifestations of psychotic disorders. Navane has not been evaluated in the management of behavioral complications in patients with mental retardation. Contraladlcatlens: Contraindicated in patients with circulatory collapse, comatose states, central nervous system depression due to any cause, and blood dyscrasias. Contraindicated in individuals who have shown hypersensitivity to the drug. It is not known whether there is a cross-sensitivity between the thioxanthenes and the phenothiazrne derivatives, butthe possibility shou be coniadered Warnings: Tardive Oyskinesia-Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with neuroleptic antipsychotic ; drugs. Afthoughthe prevalence ofthe syndrome appearsto be highest among theelderfy, especiallyeldertywomen, it is impossibleto rely upon prevalence estimates to predict, atthe inception of neuroleptic treatment, which patients are likely to develop the syndrome. Whether neuroleptic drug products difler in their potential to cause tardive dyskinesia is unknown. Both the risk of developing the syndrome and the likelihood that it will become irreversible are believed to increase as the duration oftreatment and the total cumulative dose of neuroleptic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly after relatively brief treatment periods at low doses. There is no known treatment for established ses of tardive dyskinesia, although the syndrome may remit, partially or completely, if neuroleptictreatment is withdrawn. Neuroleptictreatment, itself, however, may suppress or partially suppress ; the signs and symptoms of the syndrome and thereby may possibly mask the underlying disease ocess The effect that symptomatic suppression has upon the long-term course ofthe syndrome is unknown. Given these considerations, neuroleptics should be prescribed in a manner that is most likelyto minimize the occurrence of tardive dyskinesia Chronic neuroleptic treatment should generally be reserved for patents who sufferfrom a chronic illnessthat, 1 ; is knownto respond to neuroleptic drugs, and, 2 ; for whom alternative, equally eflective, but potentially less harmful treatments are notavailable or appropriate. In patients who do require chronic treatment, the smallest doseand the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically. If signs and symptoms of tardive dyskinesia appear in a patient on neuroleptics, drug discontinuation should be considered. However, some patients may require treatment despite the presence of the syndrome. For further information about the description of tardive dyskinesia and its clinical detection, please refer to Information for Patients in the Precautions section, and to the Adverse Reactions section. ; Neuroleptic Malignant Syndrome NMS ; -A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome NMS ; has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability irregular pulse w blood pressure, tachycardia, diaphoresis, and cardiac dysrhythimas ; . The diagnoslic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases wherethe clinical presentation includes both serious medical illness e.g. , pneumonia, systemic infection, etc. ; and untreated or inadequately treated extrapyramidal signs and symptoms EPS ; . Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system CNS ; pathology. The management of NMS should include 1 ; immediate discontinuation of antipsychotic drugs and other drugs notessentialto concurrenttherapy, 2 ; intensive symptomatictreatmentand medical monitoring and 3 ; treatmentofanyconcomitantsenous medical problemsforwhich specifictreatmentsareavailable. There is no general agreementabout specific pharmacoIocaltreatment regimens for uncomplicated NMS. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient shoiud be carefully monitored, since recurrences of NNS have been reported. Usage in Pregnancy-Safe use of Navane dunng pregnancy has not been established. Therefore, this drug shoid be given to pregnant patients onlywhen, in the judgmentofthe physician, the expected benefits from the treatment exceed the possible risks to mother and fetus. Animal reproduction studies and clinical experienceto date have notciemonstrated anyteratogenic effects. In the animal reproduction studies with Navane, there was some decrease in conception rate and litter size, and an increase in resorption rate in rats and rabbits, changes which have been similarly reported with other psychotropic agents. After repeated oral administration of Navane to rats 5 to 15 mg kg day ; , rabbits 3 to 50 mg kg day ; , and monkeys 1 to 3 mg kg day ; before and during gestation, no teratogenic effects were seen. See Precautions. ; Usage in Children-The use of Navane in children under 12 years of age is not recommended because safety and efficacy in the pediatric age group have not been established. As is true with many CNS drugs, Navane may impair the mental and or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery, especially dunng the first few days of therapy. Therefore, the patient should be cautioned accordingly. As in the case of other CNS-acting drugs, patients receiving Navane should be cautioned about the p05sible additive effects which may include hypotension ; with CNS depressants and with alcohol. Precautions: An antiemetic effect was observed in animal studies with Navane: since this effect may also occur in man, it is possible that Navane may mask signs of overdosage of toxic drugs and may obscure conditions such as intestinal obstruction and brain tumor. In consideration of the known capability of Navane and certain other psychotropic drugs to precipitate convulsions, extreme caution should be used in patients with a history of convulsive disorders orthose in a state of alcohol withdrawal since it may lower the convulsive threshold. Although Navane potentiates the actions ofthe barbiturates, the dosage ofthe anticonvulsant therapy should not be reduced when Navane is administered concurrently. Caution as well as careful adjustment of the dosage is indicated when Navane is used in conlunction with other CNS depressants other than anticonvulsant drugs. Though exhibiting ratherweakanticholinergic properties, Navarie shotud be used with caution in patients who are known or suspected to have glaucoma, or who might be exposed to extreme heat, or who are receivrng atropsne or related drugs. Use with caution in patients with cardiovascular disease. Also, careful observation should be made for pigmentary retinopathy, and lenticular pigmentation fine lenticular pigmentation has been noted in a small number of patients treated with Navane for prolonged.